Thomas Dejoie

机构：Centre Hospitalier Universitaire de Nantes, Centre d'Investigation Clinique de Nantes · ORCID：0000-0002-5080-6585

发表论文 110 篇 · 总被引 3518 次 · h-index 24

代表论文

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial (2024 · The Lancet Oncology · 被引 119)
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results (2025 · Blood · 被引 23)
M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator (2023 · Clinical Chemistry and Laboratory Medicine (CCLM) · 被引 11)
N-linked glycosylation of the M-protein variable region: glycoproteogenomics reveals a new layer of personalized complexity in multiple myeloma (2024 · Clinical Chemistry and Laboratory Medicine (CCLM) · 被引 8)
Effectiveness of intraoperative use of dexmedetomidine in reducing the incidence of tachyarrhythmia after congenital cardiac surgery in neonates and infants: a doubly robust method estimation analysis (2023 · European Journal of Cardio-Thoracic Surgery · 被引 6)
An automated workflow based on data independent acquisition for practical and high-throughput personalized assay development and minimal residual disease monitoring in multiple myeloma patients (2024 · Clinical Chemistry and Laboratory Medicine (CCLM) · 被引 4)